Jusdap 10 Tablet contains Dapagliflozin 10 mg, a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated for the management of type 2 diabetes mellitus. By inhibiting SGLT2 in the proximal renal tubules, Dapagliflozin reduces glucose reabsorption and increases urinary glucose excretion, thereby lowering plasma glucose levels. Jusdap 10 is prescribed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It may be used as monotherapy when metformin is contraindicated or not tolerated, or in combination with other antidiabetic agents including insulin. Clinical studies have demonstrated that Dapagliflozin not only improves glycemic parameters such as HbA1c but also contributes to modest weight loss and reduction in blood pressure, offering cardiovascular and renal benefits. The drug is generally well tolerated; however, potential adverse effects include urinary tract infections, genital mycotic infections, and volume depletion-related symptoms. Caution is advised in patients with renal impairment, and it is contraindicated in type 1 diabetes and diabetic ketoacidosis. Regular monitoring of renal function and glycemic status is recommended during therapy. Jusdap 10 Tablet should be used under medical supervision with appropriate lifestyle modifications for optimal diabetes management.